13D·WATCH Activist + Insider Intelligence Live feed Blog About Pilot
SCHEDULE Filed 2025-02-14 Event 2025-02-14 SEC 0001104659-25-014140 →

Sofinnova Crossover I Abivax S.A. AAVXF

Stake: 11.00% Shares: 7,794,478 CUSIP: 00370M103 Class: Ordinary Shares, par value EUR0.01 per share

Item 4 — Purpose of Transaction

Item 4 of the Schedule 13D is hereby amended and supplemented as follows: Under French law, shares registered for more than two years in the name of the same shareholder are automatically granted double voting rights, unless the by-laws expressly reject this measure. Consequently, on July 6, 2024, SC received an additional 261,865 voting rights and on October 22, 2024, SC received an additional 584,000 voting rights. SC may, from time to time, acquire additional Ordinary Shares and/or ADSs or sell all or a portion of the Ordinary Shares and/or ADSs held by SC in the open market or in privately negotiated transactions, or may distribute the Ordinary Shares and/or ADSs held by SC to its unitholders. Any actions SC might undertake will be dependent upon its review of numerous factors, including, among other things, the market prices of the Ordinary Shares and ADSs, general market and economic conditions, ongoing evaluation of the Issuer's business, financial condition, operations and prospects, the relative attractiveness of alternative business and investment opportunities, investors' need for liquidity, and other future developments. Except as described in this Schedule 13D, the Reporting Persons do not have any present plans or proposals that relate to or would result in any of the actions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D, although, the Reporting Persons, at any time and from time to time, may review, reconsider and change their position and/or change their purpose and/or develop such plans and may seek to influence management or the Board of Directors of the Issuer with respect to the business and affairs of the Issuer and may from time to time consider pursuing or proposing such matters with advisors, the Issuer or other persons.

Cross-References

Insider Activity (last 365d)
0 transactions
0 buys · 0 sales · 0 awards/exercises
Issuer Cluster
1 13D/G filings on this issuer
0 other filings besides this one
Filer Track Record
1 filings by this filer
0 other filings in the data moat
Short Interest · settle 2026-03-31
DTC 999.99
10,288 shares short · -8.3% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers
1 holder · $392.31M
Point72 Asset Mgmt

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. $1,500/mo. Pilots welcome.

Request a pilot →